Certara (CERT) to Release Quarterly Earnings on Thursday

Certara (NASDAQ:CERT) is projected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $103.2290 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Certara Stock Performance

NASDAQ:CERT opened at $6.49 on Tuesday. The firm has a 50-day moving average of $8.53 and a two-hundred day moving average of $9.99. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a market cap of $1.03 billion, a P/E ratio of 92.71 and a beta of 1.47. Certara has a 1-year low of $6.32 and a 1-year high of $15.38.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CERT. T. Rowe Price Investment Management Inc. grew its position in Certara by 580,097.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock valued at $7,310,000 after buying an additional 829,540 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of Certara in the 4th quarter worth approximately $111,000. nVerses Capital LLC acquired a new position in shares of Certara during the fourth quarter valued at approximately $184,000. Toronto Dominion Bank increased its stake in shares of Certara by 186.9% during the fourth quarter. Toronto Dominion Bank now owns 83,939 shares of the company’s stock valued at $739,000 after acquiring an additional 54,677 shares during the period. Finally, Oxford Asset Management LLP bought a new stake in Certara during the fourth quarter worth approximately $256,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of recent analyst reports. Stephens cut their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. Barclays reduced their target price on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Rothschild & Co Redburn set a $10.00 price target on Certara in a report on Friday, November 21st. BMO Capital Markets initiated coverage on shares of Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 target price for the company. Finally, KeyCorp reduced their price target on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.82.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.